Fludarabine induces apoptosis, activation, and allogenicity in human endothelial and epithelial cells: protective effect of defibrotide
- 1 July 2002
- journal article
- Published by American Society of Hematology in Blood
- Vol. 100 (1) , 334-340
Abstract
Fludarabine is a nonmyeloablative immunosuppressant increasingly used as a component of alternative conditioning regimens before allogeneic bone marrow transplantation. It is expected to reduce conditioning-related toxicity and proinflammatory activation of the host tissues. However, in our in vitro study, we provide evidence that 2-fluoroadenine 9-β-d-arabinofuranoside (F-Ara) as the active metabolized form of fludarabine damages human microvascular endothelial cells (HMECs) and dermal and alveolar epithelial cell lines after 48 hours of culture when it is used in pharmacologically relevant concentrations (range, 10 μg/mL-1 μg/mL). In addition, flow cytometric analyses revealed a significant up-regulation of intercellular adhesion molecule 1 and major histocompatibility complex (MHC) class I molecules by F-Ara, suggesting a proinflammatory activation of HMECs. Cytotoxicity assays demonstrated that target HMECs pretreated with F-Ara (10 μg/mL) showed increased lysis by allogeneic MHC class I-restricted cytotoxic T lymphocytes from healthy human donors. We conclude that, beside its immunosuppressive activities, F-Ara can be harmful for target tissues of transplantation-related complications and can even stimulate allogeneic immune responses. We identified the pharmaceutical compound defibrotide as protective against F-Ara– induced apoptosis and alloactivation, importantly, without affecting the antileukemic effect of F-Ara. This observation argues for a potential clinical usage of defibrotide in pretransplantation conditioning.Keywords
This publication has 35 references indexed in Scilit:
- Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use studyBritish Journal of Haematology, 2000
- Rapid achievement of complete donor chimerism and low regimen-related toxicity after reduced conditioning with fludarabine, carmustine, melphalan and allogeneic transplantationBone Marrow Transplantation, 2000
- Mini-allografts: ongoing trials in humansBone Marrow Transplantation, 2000
- Protectant Activity of Defibrotide in Cardioplegia Followed by IschernialReperfusion Injury in the Isolated Rat HeartJournal of Cardiac Surgery, 1999
- REGULATION OF IMMUNE RESPONSES THROUGH INHIBITORY RECEPTORSAnnual Review of Immunology, 1999
- Influence of bacterial endotoxin on the allogenicity of human endothelial cellsBone Marrow Transplantation, 1998
- INFLUENCE OF BACTERIAL ENDOTOXIN ON RADIATION-INDUCED ACTIVATION OF HUMAN ENDOTHELIAL CELLS IN VITRO AND IN VIVOTransplantation, 1997
- INFLUENCE OF BACTERIAL ENDOTOXIN ON RADIATION-INDUCED ACTIVATION OF HUMAN ENDOTHELIAL CELLS IN VITRO AND IN VIVOTransplantation, 1996
- Accessory Function of Endothelial Cells in Anti-CD3-Induced T-Cell Proliferation: Synergism with MonocytesScandinavian Journal of Immunology, 1992
- Gene deletion, a mechanism of induced mutation by arabinosyl nucleosidesMutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 1989